National Genecular Institute Testifies in Favor of Iowa Bill to Ease Restrictions on Stem Cell Research
News Feb 22, 2007
The National Genecular Institute (NGI) has announced Dr. Tannin Fuja, director of research and chief scientific officer, will testify a public hearing in support of the Iowa Stem Cell Research and Cures Initiative.
The Bill, House File 287, would ease restrictions on stem cell research and enable medical researchers to create embryonic stem cells through cloning in order to find cures and treatments for diseases. It was recently approved by the Iowa House Human Resources Committee and will be the focus of public hearing at the Iowa State House in Des Moines.
Dr. Fuja, who is also an adjunct faculty member at the University of Iowa, is leading NGI’s development of the world’s largest global biotrust facility in conjunction with the University of Iowa.
Hundreds of thousands of tissue and DNA samples will be collected, cultivated, stored and sold to third-party researchers for studies into diseases such as Parkinson’s disease, Alzheimer’s disease, certain cancers and MS.
“While embryonic stem cell research is currently being conducted in Iowa, under the current law this research cannot be used for treatment and therapies,” said Fuja.
“Embyronic stem cell research holds tremendous promise for improving the lives of millions of Americans and offers a powerful tool in the advancement of biomedical discovery and cure that is critically distinct from that of adult or fetal stem cell research. This is why we strongly urge the Iowa congress to support the repeal of the ban on embryonic stem cell research in Iowa,” Fuja continued.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.